For an exclusive license to the preclinical Lp(a) disruptor, AstraZeneca is paying CSPC Pharmaceutical Group $100 million ...
The clinical hold doesn’t cover its drug’s Investigational New Drug application for autoimmune hepatitis, for which the Phase ...
J&J has recently pulled back from the infectious diseases space, including winding down R&D activity in this area in August ...